Pergolide: long-term use in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Mayo Clinic proceedings

• Publication date

  1988-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0025-6196(12)64912-XPMID 3050301
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dopamine receptors in the parkinsonian brain

  2005cited by this paper
• Study of deterioration in long-term treatment of parkinsonism with L-Dopa plus decarboxylase inhibitor

  2005cited by this paper
• Dopamine receptor agonists: Intrinsic activity vs. state of receptor

  2005cited by this paper
• Treatment of Parkinson's disease with pergolide: a double-blind study.

  1988cited by this paper
• Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions?

  1987cited by this paper
• Parallel double-blind study of pergolide in Parkinson's disease.

  1987cited by this paper
• Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.

  1987cited by this paper
• On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics

  1987cited by this paper
• Overview of morphological changes in Parkinson's disease.

  1987cited by this paper
• Long‐term follow‐up of early dopa treatment in Parkinson's disease

  1986cited by this paper
• Long‐term study of pergolide in Parkinson's disease

  1985cited by this paper
• Double‐blind trial of pergolide for Parkinson's disease

  1985cited by this paper
• Chronic levodopa or pergolide administration induces down‐regulation of dopamine receptors in denervated striatum

  1984cited by this paper
• Long‐term treatment with pergolide

  1984cited by this paper
• Altered pharmacokinetics of L‐dopa metabolism in rat striatum deprived of dopaminergic innervation

  1984cited by this paper
• Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.

  1983cited by this paper
• Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy

  1983cited by this paper
• Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

  1979cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Neurotransmitter receptor alterations in Parkinson's disease.

  1977cited by this paper
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper
• Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

  1975cited by this paper
• 3-O-Methyldopa in Parkinson's disease.

  1974cited by this paper
• Parkinsonism

  1967cited by this paper

• Economic and Health-Related Quality of Life Considerations of New Therapies in Parkinson’s Disease

  2012cites this paper
• Role of dopamine receptor agonists in the treatment of early Parkinson's disease.

  2009cites this paper
• Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations

  2005cites this paper
• A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation.

  2004cites this paper
• Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2).

  2002cites this paper
• Management of Parkinson's disease: An evidence‐based review

  2002cites this paper
• Chapter 9 Clinical Trials in Parkinson's Disease

  2001cites this paper
• Long-term treatment with dopamine agonists in idiopathic in Parkinson's disease

  2000cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Dopamine agonists.

  1999cites this paper
• Klinik — orale Medikation

  1999cites this paper
• [Motor complications of treatment with levodopa in Parkinson's disease].

  1999cites this paper
• Rationale for Use of Dopamine Agonists in Parkinson's Disease: Review of Ergot Derivatives

  1999cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease

  1999cites this paper
• Advances in the treatment of Parkinson's disease.

  1998cites this paper
• Pergolide

  1997cites this paper
• Psychosis during Chronic Levodopa Therapy Triggered by the New Antidepressive Drug Mirtazapine

  1997cites this paper
• [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].

  1997cites this paper
• Therapie des Morbus Parkinson Teil 1: Standardtherapie motorischer und nicht motorischer Symptome

  1997cites this paper
• Dopamine agonists in the treatment of Parkinson's disease.

  1995cites this paper
• Pergolide mesylate in Parkinson's disease treatment.

  1995cites this paper
• Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

  1994cites this paper
• Ibopamine-induced reversible leukopenia during treatment for congestive heart failure.

  1993cites this paper
• Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.

  1992cites this paper
• Parkinsonism Treatment: Part III—Update

  1992cites this paper
• Pergolide in the treatment of Parkinson's disease.

  1991cites this paper
• Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.

  1990cites this paper
• Pergolide-Induced Hypotension

  1990cites this paper
• Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.

  1989cites this paper
• Pergolide in the treatment of Parkinson's disease

  1984cites this paper